PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Naziye Ak

Istanbul University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 8, 2026 · JOURNAL ARTICLE

Durable complete response after a single cycle of pembrolizumab-based chemoimmunotherapy in metastatic squamous cell lung cancer: a case report

Discover Oncology

A single case report of an unusual clinical outcome in metastatic squamous cell lung cancer; descriptive rather than comparative, and explicitly noted as 'exceedingly rare', raising hypothesis about durability rather than establishing generalizable evidence.

PreliminaryNaziye Ak Lung Cancer Treatments and Mutations Simay Çokgezer

Reported

Time to complete remission assess…24 months

PD-L1 tumor proportion score40%

Number of treatment cycles1

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support